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Abstract: Topical therapies offer a nonsurgical method for treating conjunctival tumors by 
delivering high drug concentrations to the ocular surface. Over the past ten years, topical agents 
have been used by investigators to treat various premalignant and malignant lesions of the con-
junctiva, such as primary acquired melanosis with atypia, conjunctival melanoma, squamous 
intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva, and pagetoid spread of 
the conjunctiva arising from sebaceous cell carcinoma. Despite the enthusiasm generated by the 
success of these agents, there are unanswered questions regarding the clinical efﬁ  cacy of this new 
nonsurgical approach, and whether a single topical agent can achieve cure rates comparable with 
traditional therapies. Furthermore, the long-term consequences of prolonged courses of topical 
chemotherapeutic drugs on the ocular surface are unknown, and the ideal regimen for each of 
these agents is still being reﬁ  ned. In this review, we present speciﬁ  c guidelines for treating both 
melanocytic and squamous neoplasms of the conjunctiva, utilizing the available data in the lit-
erature as well as our own clinical experience at the Memorial Sloan-Kettering Cancer Center.
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Introduction
Historically, the established method of treatment for conjunctival neoplasms has been 
wide local excision, with or without supplemental cryotherapy to the surgical margins. 
Unfortunately, conjunctival neoplasms can be diffuse or multifocal, with borders that 
are difﬁ  cult to detect clinically or even with histopathologic examination. Topical 
therapies offer a nonsurgical method for treating the entire conjunctival surface with 
less dependence on deﬁ  ning tumor margins. Topical administration can also deliver 
high drug concentrations to the ocular surface with negligible systemic side effects. 
Unlike surgical excision, topical treatments can be titrated and even repeated according 
to the clinical response. The cost is typically minimal when compared with surgical 
intervention, and there is little risk of spreading neoplastic cells with topical therapy. 
Because of these potential advantages, there has been growing interest in the use of 
topical agents for various conjunctival neoplasms.
Over the past ten years, topical agents have been used by investigators to treat 
various premalignant and malignant lesions of the conjunctiva, such as primary 
acquired melanosis with atypia, conjunctival melanoma, squamous intraepithelial 
neoplasia and squamous cell carcinoma of the conjunctiva, and pagetoid spread of the 
conjunctiva arising from sebaceous cell carcinoma. Despite the enthusiasm generated 
by the success of these agents, it should be kept in mind that chemotherapeutic drugs 
can be potentially toxic to the ocular surface. There are also issues with compliance 
that do not exist with traditional therapies. The long-term consequences of prolonged 
courses of topical chemotherapeutic agents on the ocular surface are unknown, and the 
ideal regimen for each of these agents is still being reﬁ  ned. Perhaps most importantly, 
there are unanswered questions regarding the clinical efﬁ  cacy of this new nonsurgical Clinical Ophthalmology 2008:2(3) 504
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approach, and whether a single topical agent can achieve 
long-term cures of conjunctival neoplasms.
The goal of this review is to summarize the essential 
published literature on the use of topical agents for both 
melanocytic and squamous conjunctival neoplasms. Further-
more, our aim is to offer speciﬁ  c therapeutic guidelines for 
clinicians using the available data that has been published 
by various investigators, augmented by our own clinical 
experience at the Memorial Sloan-Kettering Cancer Center 
in New York, NY. To accomplish these goals, we reviewed 
the relevant medical literature by searching MEDLINE 
(1970–2006) for articles describing the use of topical che-
motherapy agents for conjunctival neoplastic processes. In 
performing this search, the following keywords were used 
both singly and in combination: chemotherapy, topical, 
mitomycin, 5-ﬂ  uorouracil, interferon, conjunctival neoplasm, 
conjunctival tumor, primary acquired melanosis (PAM), 
conjunctival melanoma, squamous cell carcinoma, ocular 
surface squamous neoplasia, conjunctival papilloma, and 
sebaceous cell carcinoma. Additional articles were identiﬁ  ed 
by reviewing the bibliographies of publications found in the 
MEDLINE search.
Topical agents for conjunctival 
neoplasms
Mitomycin-C
Mitomycin C (MMC) is an alkylating agent that binds to 
DNA during all phases of the cell cycle, leading to irrevers-
ible cross-linking and inhibition of nucleotide synthesis. 
Isolated from Strepmyces caespitosus, enzymatic reduction 
of its quinine ring and methoxy group permits MMC to cross 
link DNA between adenine and guanine at three different 
sites (McKelvie and Daniell 2001). Under aerobic conditions, 
intermediates of MMC also react with molecular oxygen to 
generate free radicals, causing cytotoxicity via lipid peroxida-
tion. Hence, MMC appears to be toxic to both proliferating 
and nonproliferating cells. In clinical oncology, MMC has 
been used extensively to treat superﬁ  cial transitional cell 
carcinoma of the bladder epithelium (Murphy, Soloway 
et al 1981). In its ophthalmic use, MMC has an established 
track record for safety and efﬁ  cacy in pterygium and glau-
coma surgery (Palmer 1991; Donnenfeld et al 2003). When 
applied to conjunctival surfaces as a surgical adjunct, MMC 
has been shown to inhibit ﬁ  broblast cell migration, decrease 
extracellular matrix production, and to induce apoptosis in 
Tenon’s capsule ﬁ  broblasts. It is well known that chronic 
tissue effects from topical MMC administration can persist 
for many years after the cessation of treatment, similar to the 
effects of ionizing radiation (Demirci et al 2000; McKelvie 
and Daniell 2001).
Topical MMC has been reported to cause various histo-
pathologic changes to the conjunctival epithelium. Folberg 
and associates (1999) reported an analysis of 18 conjunctival 
biopsy specimens taken from ten patients treated with MMC 
for PAM with atypia (Salomao et al 1999). The patients in 
this study were treated with topical 0.02% MMC for 14–21 
consecutive days, with biopsies being performed 3–6 weeks 
following the last day of therapy. In these conjunctival 
specimens, epithelial cells consistently demonstrated dys-
plastic changes, such as nuclear enlargement and chromatin 
hyperchromasia, but only in the superﬁ  cial layers of the 
conjunctival epithelium. The authors also emphasized that 
an enlargement of the nucleus and the cell appeared to occur 
proportionately (ie, cytomegaly), resulting in a preserved 
nucleus-cytoplasmic ratio. Other histopathologic features 
included cytoplasmic condensation and eosinophilia, focal 
epithelial sloughing, and single cell necrosis, all suggestive 
of apoptosis. The authors commented that the distinction 
between chemotherapy effect and recurrent neoplasm was 
less problematic in patients with PAM since the atypical 
cells following topical MMC were superﬁ  cially located, 
while the melanocytes of PAM were in the basal layers of the 
epithelium. Conversely, degenerative changes in the normal 
conjunctival epithelium induced by topical MMC may be dif-
ﬁ  cult to distinguish from recurrent or persistent conjunctival 
squamous neoplasia (Nadjari et al 1999). In a report by Nad-
jari and colleagues (1999), cytology samples were taken 2 
weeks following the completion of topical MMC therapy for 
conjunctival intraepithelial neoplasia (CIN). Not only were 
there cellular changes such as chromatin clumping, nuclear 
pyknosis, and cytoplasmic vacuolization, DNA cytometric 
analysis revealed aneuploidy in nonneoplastic squamous cells 
(Nadjari et al 1999). Despite the cellular changes induced 
by topical MMC treatment, the nucleus to cytoplasmic ratio 
remained constant in nonneoplastic cells, whereas this ratio 
increased markedly with recurrent CIN (Nadjari et al 1999; 
McKelvie and Daniell 2001). McKelvie and Daniell (2001) 
reported the long-term results of impression cytology follow-
ing topical MMC therapy for ocular surface squamous neo-
plasia. Samples from four patients with primary or recurrent 
ocular surface squamous neoplasia (OSSN) were analyzed 
between 4 and 17 weeks after topical MMC therapy. The 
predominant form of cell death in dysplastic cells appeared 
to be apoptosis, although areas of necrosis were also seen. 
Apoptotic bodies were identiﬁ  ed up to 12 weeks after starting Clinical Ophthalmology 2008:2(3) 505
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topical therapy, although there were fewer numbers of these 
cells with longer durations of treatment. Dysplastic cellular 
changes were also seen in the normal epithelial cells, includ-
ing cytoplasmic vacuolization, cytomegaly, and multiple 
nuclei or binucleation; these changes persisted up to 8 months 
after the completion of topical MMC treatment (McKelvie 
and Daniell 2001). Chronic histopathologic changes to the 
conjunctival epithelium had also been reported by Demirci 
and colleagues (2000) in patients treated with topical MMC. 
In patients who had received between 7–28 days of topical 
MMC, the authors showed that there was diffuse conjunctival 
epithelial atrophy and thinning, dyskeratosis, focal keratini-
zation, and stromal ﬁ  brosis in areas with atrophic epithelium. 
The authors noted that these conjunctival changes persisted 
for an extended period even after the treatment was discon-
tinued, similar to the long-term effects of ionizing radiation 
(Demirci et al 2000; McKelvie and Daniell 2001).
When prescribing topical MMC for the treatment of 
conjunctival neoplasms, certain precautions should be taken. 
Patients and their families are advised to wear latex gloves at 
all times when handling the medication, and pregnant women 
should avoid any contact with the drug. MMC is relatively 
unstable in solution and its action decreases in 8–10 days 
(Midena et al 2000). Therefore, the formulation for topical 
MMC needs to be refrigerated and a new bottle dispensed for 
each week of treatment. Since MMC is a chemotherapeutic 
agent, all residual bottles should be returned to the pharmacy 
for proper disposal. Patients should also be instructed to 
occlude their puncta for at least 5 minutes after the topical 
instillation of MMC to avoid nasopharyngeal and systemic 
exposure to the drug.
5-Fluorouracil
Similar to MMC, topical 5-FU has also been used to inhibit 
the proliferation of subconjunctival ﬁ  broblasts after glau-
coma ﬁ  ltration surgery (Katz et al 1995). Several reports 
have also conﬁ  rmed the clinical efﬁ  cacy of topical 5-FU in 
the treatment of preinvasive ocular surface neoplasia (Yeatts 
et al 1995, 2000; Midena et al 2000). 5-FU is an antime-
tabolite used to treat many epithelial cancers because of its 
actions on rapidly proliferating cells. Within the cell, the 
drug inhibits thymidylate synthetase during the S phase of 
the cell cycle, preventing DNA and RNA synthesis in rapidly 
dividing cells because of a lack of thymidine. Although the 
1% dose of 5-FU used in clinical studies is somewhat arbi-
trarily chosen, this dosage appears to be well-tolerated in the 
vast majority of patients. In addition, the cytologic changes 
associated with MMC have not been observed with topical 
5-FU (de Keizer et al 1986; Yeatts et al 2000). Finally, 5-FU 
is an inexpensive drug, easily handled by medical personnel 
and patients, and is stable in aqueous solution for at least 
3 weeks. 5-FU also does not require refrigeration, as does 
MMC (Midena et al 2000).
Alpha-Interferon
Interferons are a family of glycoprotein molecules that act 
at cell surface receptors to produce antiviral and antitumor 
activities through direct and indirect mechanisms (Baron 
et al 1991; Schechter et al 2002). Systemic interferon-alpha 
is an established therapeutic agent for hairy cell leukemia, 
condyloma acuminate, Kaposi’s sarcoma in AIDS, and 
hepatitis (both B and C). Intralesional interferon has also 
been reported to be effective at treating squamous and basal 
cell carcinomas of the skin (Fenton et al 2002). Topical 
IFNapha2b is the recombinant form of interferon-alpha, and 
this formulation has been shown to be effective for treating 
conjunctival and corneal intraepithelial neoplasia (CIN) 
(Vann and Karp 1999). The mechanism of action for treat-
ing CIN may be related to an indirect antiproliferative effect 
of topical interferon on superﬁ  cial tumor cells, achieved by 
promoting the immune response through an activation of 
host cytotoxic effector cells (Baron et al 1991).
Conjunctival neoplasms treated 
with topical agents
Primary acquired melanosis 
and conjunctival melanoma
Primary acquired melanosis is a proliferative condition of 
melanocytes that populate the conjunctival epithelium (Fol-
berg et al 1984, 1985b). Clinically, PAM presents as a super-
ﬁ  cial ﬂ  at, brown discoloration of the conjunctiva that most 
commonly affects middle-aged or older Caucasian patients. 
The margins of PAM may be indistinct and difﬁ  cult to iden-
tify clinically, particularly if there are variably pigmented or 
nonpigmented areas. The extent of conjunctival involvement 
with PAM may also increase and decrease over time. There 
are two distinct histologic subtypes: PAM without atypia is 
characterized by benign-appearing melanocytes that populate 
the basilar epithelium, whereas PAM with atypia is char-
acterized by cytologically abnormal melanocyte subtypes, 
such as polyhedral cells, spindle cells, large dendritiform 
cells, or epithelioid cells. The abnormal cells that character-
ize PAM with atypia may remain restricted to the basilar 
region or spread to all level of the epithelium. PAM without 
atypia appears to have minimal malignant potential, whereas Clinical Ophthalmology 2008:2(3) 506
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PAM with atypia may progress to malignant melanoma in 
up to 46% of cases (Folberg et al 1984). Cases of PAM with 
atypia demonstrating certain histopathologic features, such 
as epithelioid cells or pagetoid extension, carry a 75%–90% 
chance of transforming into invasive melanoma (Jakobiec 
et al 1989). The median time for PAM with atypia to progress 
to melanoma is approximately 2.5 years, but it may take as 
long as 10 years (Folberg et al 1985b). Malignant melanoma 
of the conjunctiva is commonly associated with PAM with 
atypia, although it can also arise de novo or from conjunctival 
nevi (Folberg et al 1985a). The incidence of conjunctival 
melanoma is only 0.2–0.8 per million in Caucasian popula-
tions (Seregard and Kock 1992; Seregard 1998), but it is 
a potentially lethal ocular malignancy with an overall 10 
year mortality as high as 26%–30% (De Potter et al 1993; 
Seregard 1998).
Currently, surgical resection with cryotherapy applied to 
the conjunctival margins is the most commonly employed 
method for treating PAM with atypia. However, using the 
pigmented margins to deﬁ  ne the extent of resection is often 
problematic due to the diffuse or amelanotic features of these 
tumors. Local recurrence rates for PAM with atypia after 
local excision and cryotherapy range between 24%–79% 
with long-term follow-up (Paridaens et al 1994; Shields et al 
2001). Recurrences are typically associated with incomplete 
excision, corneal involvement, and/or multifocal disease. The 
established management approach for invasive conjunctival 
melanoma is wide surgical excision, although with long-term 
follow-up nearly 50%–60% of patients manifest local recur-
rence (Liesegang and Campbell 1980; Paridaens et al 1994; 
Demirci et al 2000). Despite orbital exenteration, 33%–50% 
of patients with conjunctival melanomas develop metastatic 
disease when the thickness of the primary tumor exceeds 
1.0 mm (Paridaens et al 1994).
Melanocytic lesions and MMC
Over the past decade, there have been numerous papers 
describing the use of topical MMC for both PAM with atypia 
and conjunctival melanoma (Finger et al 1993; Frucht-Pery 
and Pe’er 1996; Demirci et al 2000; Shields et al 2001; 
Rodriguez-Ares et al 2003; Yuen et al 2003; Kurli and 
Finger 2005). Finger and colleagues (1993) described the 
use of topical MMC as a treatment modality for conjuncti-
val melanomas. Since then, his group has published several 
papers describing their clinical experience with this treatment 
approach (Demirci et al 2000; Kurli and Finger 2005). In 
2005 they published the long-term results of 16 patients with 
biopsy-proven PAM with atypia (8 patients) or conjunctival 
MM (8 patients) treated with topical MMC (Kurli and Finger 
2005). When MMC was used as primary therapy, the regimen 
used in their protocol was one drop of 0.04% MMC instilled 
into the superior conjunctival fornix four times a day for 14 
days, discontinuing treatment for 14 days, and then restarting 
MMC for a second 14 day course of treatment. When given 
as an adjuvant to surgical excision and cryotherapy, MMC 
was given for 7 days starting within 2 weeks of surgery. In 
this study, topical MMC was used as primary therapy in 8 
patients with PAM with atypia, in 2 patients with invasive 
melanoma, and in 6 patients as adjunctive therapy following 
surgical excision for conjunctival melanoma. Interestingly, 
all 16 patients in his case series demonstrated a clinical 
response to topical MMC, deﬁ  ned as regression of the areas 
of pigmentation. With long-term follow-up, however, ﬁ  ve 
of the ten patients in the primary treatment group developed 
tumor recurrence: 3/8 patients with PAM with atypia and 2/2 
patients with melanoma. For the 6 patients in the adjuvant 
group, 2 developed tumor recurrences during the follow-up 
period. Overall, surgical excision was performed in 8 of the 
16 cases for tumor recurrence, and 3 cases required orbital 
exenteration. One of the patients with invasive melanoma 
treated with MMC as primary therapy had subepithelial 
nests of melanoma which were resistant to repeated courses 
of topical treatment. Despite orbital exenteration, this patient 
ultimately developed metastatic disease 42 months after the 
initial course of topical MMC. Because of this patient, the 
authors commented that they were reluctant to use topical 
MMC as primary treatment for any patient with nodules of 
invasive melanoma.
Another advocate of topical MMC for conjunctival 
melanocytic lesions is the group at the Hadassah University 
Hospital in Jerusalem, Israel (Frucht-Pery and Ilsar 1994; 
Frucht-Pery and Pe’er 1996; Frucht-Pery et al 2002; Pe’er 
and Frucht-Pery 2005). Frucht-Pery and Pe’er (1996) suc-
cessfully treated a 63 year old woman with diffuse PAM with 
atypia. They treated the patient with two 14 day courses of 
treatment, the ﬁ  rst with 0.2 mg/ml concentration and the sec-
ond with 0.4 mg/ml concentration. The diffuse pigmentation 
cleared and a repeat biopsy showed no evidence of atypia. A 
follow-up paper in 2005 described a series of 12 consecutive 
patients treated by their group with topical MMC for melano-
cytic lesions of the conjunctiva (Pe’er and Frucht-Pery 2005). 
Among the 12 patients, 9 had PAM with atypia and 3 had 
invasive melanoma. The patients in their protocol (except the 
ﬁ  rst patient) used 0.04% MMC 4 times per day for 2 weeks, 
with pauses of 2 weeks between courses, until “disappear-
ance or stabilization of the remnants of the pigmentation” Clinical Ophthalmology 2008:2(3) 507
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(Pe’er and Frucht-Pery 2005). MMC was used as primary 
treatment in all 12 cases and the duration of therapy ranged 
from 2–5 cycles. In four patients the pigmentation completely 
disappeared with MMC treatment. In the other eight patients, 
some remnants of pigmentation remained, and one of the 
patients with early invasive melanoma was noted to have a 
tumor recurrence during the follow-up period and was treated 
successfully with two more courses of MMC. This series had 
no patients that required surgical intervention, although the 
follow-up was shorter than the Kurli series (24 months vs. 
81 months) (Kurli and Finger 2005).
Although numerous papers have been published on the 
use of topical MMC for melanocytic lesions, the total number 
of patients identiﬁ  ed in this review was only 38 (6 studies) 
(Table 1). As seen in Table 1, MMC 0.04% was the most 
commonly used concentration, although 0.02% was used 
in one case by Yuen and colleagues (2003), and one case 
described by Frucht-Pery and Pe’er (1996) was treated with 
a concentration as high as 0.4 mg/ml. The most commonly 
used cycle duration was 14 days, with a period of 1–2 weeks 
between cycles; the total course of treatment was 2–3 cycles 
in most series. Overall, the clinical response rate appeared to 
be high, although a successful treatment outcome was deﬁ  ned 
somewhat differently among clinicians. Some authors deﬁ  ned 
a successful clinical response as the complete disappearance 
of pigment and/or negative biopsies after a course of topical 
treatment. Other authors deﬁ  ned clinical success as either 
stability of the areas of pigmentation or lack of progression 
of superﬁ  cial disease to invasive melanoma. For the purposes 
of our review, treatment failure was deﬁ  ned as the develop-
ment of a recurrence, either a new tumor foci or progression 
of the areas of pigmentation during the period of follow-up. 
For the group of patients with PAM without atypia treated 
with topical MMC (as primary treatment), tumor recurrence 
was noted in 3 out of 22 eyes, for a treatment failure rate of 
13.6%. However, note that all 3 cases of PAM recurrence 
were seen in the study with the longest follow-up (Kurli and 
Finger 2005), being diagnosed 23, 43, and 54 months after the 
completion of topical treatment. No patient with PAM with 
atypia treated with topical MMC was noted to progress to 
invasive melanoma during the period of follow-up, and none 
of the patients developed regional or systemic metastasis. 
When considering conjunctival melanoma, some authors 
made a distinction between lesions with microscopic inva-
sion of the basement membrane and those with invasive nests 
of nodular melanoma. For the purposes of our review, we 
grouped these lesions together since any lesion with an area 
of invasion through the basement membrane is considered 
a malignancy. For invasive melanoma, Table 1 shows that 
6 out of 16 cases were diagnosed with tumor recurrences, 
for a failure rate of 37.5%. Although one case was treated 
with additional topical therapy, the other 5 cases were treated 
with surgical excision and even exenteration in an attempt to 
obtain local tumor control. Metastasis was reported in one 
patient with malignant melanoma who received MMC as 
primary therapy (Kurli and Finger 2005).
Summary of MMC for melanocytic lesions
The interpretation of clinical studies on topical MMC is made 
difﬁ  cult by the small sample size and variation between the 
studies in tumor characteristics, previous treatment, length 
of follow-up, dosing regimen, and whether topical MMC 
was used as sole therapy, adjuvant, or intraoperative therapy. 
For PAM with atypia, the success rate of topical MMC 
compares favorably with the recurrence rate that has been 
reported following local excision and cryotherapy. Therefore, 
Table 1 Summary of clinical studies of topical MMC used as primary therapy for melanocytic lesions
Author  DX  No. eyes  Recurred  Surgery  Follow-up  MMC dose  MMC regimen
        (months)  (mg/ml)  (QID/weeks)
Frucht-Pery and Pe’er 1996  PWA  1  0  0  8  0.2%–0.4%  4
Kemp et al 2002  PWA  2  0  0  9–16  0.04%  4
Yuen et al 2003  PWA  1  0  0  26  0.02%–0.04%  16
Rodriguez et al 2003  PWA  1  0  0  36  0.04%  4
Kurli and Finger 2004  PWA  8  3  3  13–144  0.04%  2–4
Pe’er and Frucht-Pery 2005  PWA  9  0  0  6–108  0.04%  4–10
Totals PWA  22  3  3     
Rodriguez et al 2003  MM  1  0  0  36  0.04%  4
Kurli and Finger 2004  MM  8  5  5  13–144  0.04%  1–4
Pe’er and Frucht-Pery 2005  MM  3  1  0  6–108  0.04%  4–10
Totals MM  12  6  5     
Abbreviations: DX, clinical diagnosis; PWA, primary aquired melanosis with atypia; MM, malignant melanoma; QID, 4x per day.Clinical Ophthalmology 2008:2(3) 508
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topical MMC can be considered a viable therapeutic option 
for patients with diffuse PAM with atypia diagnosed on 
incisional biopsy or those patients with positive margins or 
residual areas of pigment following local excision. In most 
protocols, MMC 0.04% has been used 4 times daily for 
2 week cycles, with breaks of 1–2 weeks between cycles, 
and a total of 2–4 cycles to allow for a complete clinical 
response. It should be emphasized that not all of the areas of 
pigmentation resolve completely, and a clinical response may 
continue to be observed for months after the topical treatment 
has been stopped. Pigment that does not resolve completely 
after topical MMC therapy should not be considered a treat-
ment failure, since this may represent a grouping of normal 
melanocytes with increased pigmentation or perhaps extra-
cellular pigment (Pe’er and Frucht-Pery 2005). If a patient 
has completed an adequate course of therapy but there are 
residual areas of pigmentation, the lesion should be observed 
at regular intervals for evidence of progression or re-biopsied. 
If the area of pigment progresses during the period of follow-
up or the biopsy shows persistent disease, then patients can 
have a re-treatment with topical MMC if the area is diffuse 
or local excision if the area is fairly circumscribed.
For invasive conjunctival melanoma, the role of topical 
MMC in the treatment algorithm is not well-established. 
Among the 16 patients that have been treated with topical 
MMC as either primary or adjuvant therapy, 5 cases experi-
enced tumor recurrences (37.5%) and 3 patients eventually 
required orbital exenteration for local tumor control. It was 
noted by Demirci and colleagues (2000) that nodular nests of 
subepithelial melanoma appeared resistant to topical MMC. 
Pe’er and Frucht-Pery (2005) successfully treated 3 patients 
with conjunctival melanoma using topical MMC as primary 
therapy, although these three patients had only microscopic 
invasion on histopathology and one of the patients devel-
oped a tumor recurrence. Topical MMC was also used as an 
adjuvant agent after surgical excision by Finger’s group in 6 
patients with conjunctival melanomas, and 3 of these patients 
experienced tumor recurrences. Although the short course of 
topical therapy in these patients was well-tolerated, the ben-
eﬁ  cial effect of adjuvant MMC for conjunctival melanomas 
is questionable (Werschnik and Lommatzsch 2002). Based 
on the studies that have been published to date, caution is 
warranted when treating any patient with an invasive con-
junctival melanoma with topical MMC as primary treatment. 
If a conjunctival melanoma is surgically excised and the 
surgical margins demonstrate an area of PAM with atypia or 
residual superﬁ  cial disease of the cornea, topical therapy can 
be considered a viable alternative to repeat surgical excision. 
If the surgical margin is positive for invasive melanoma, 
surgical excision of the involved area should be strongly 
considered. This recommendation is particularly relevant for 
patients with high risk features for metastatic disease, such as 
location in the caruncle or palpebral conjunctiva, thickness 
greater than 0.8 mm, previous history of tumor recurrence, 
or pagetoid growth pattern.
Ocular surface squamous neoplasia
Lee and Hirst (1995) ﬁ  rst proposed the term OSSN to encompass 
the entire spectrum of dysplastic and carcinomatous lesions 
of the ocular surface. In its current usage, the term OSSN 
represents a spectrum of disorders from simple dysplasia 
to carcinoma in situ to invasive squamous cell carcinoma 
involving the conjunctiva, limbus, and/or cornea. OSSN 
lesions involving only the epithelium can also be termed 
conjunctival or CIN (Pizzarello and Jakobiec 1978). Similar 
to other mucosal sites, CIN can be classiﬁ  ed as mild, moder-
ate, and severe dysplasia based on the extent of involvement; 
lesions that involve the basal one-third of the conjunctiva 
are classiﬁ  ed as mild, those involving the inner two-thirds 
are classiﬁ  ed as moderate, and lesions that are full thickness 
are termed severe dysplasia or carcinoma in situ. Invasive 
disease is most commonly classiﬁ  ed as squamous cell car-
cinoma of the conjunctiva, although more rare variants such 
as mucoepidermoid and spindle cell carcinoma can be seen 
(Lee and Hirst 1995). The most common clinical presentation 
for OSSN is an elevated, vascularized lesion in the limbal 
region of older male patients who have a history of signiﬁ  cant 
exposure to ultraviolet radiation. Pizzarello and Jokobiec 
(1978) have described the macroscopic appearance of OSSN 
as being gelatinous, velvety, papilliform, or leukoplakic. 
Two other appearances, nodular and diffuse, have also been 
described (Blodi 1973). Occasionally, OSSN is diagnosed in 
younger patients with predisposing conditions, such as the 
human immunodeﬁ  ciency virus or xeroderma pigmentosum. 
Human papilloma virus (HPV) is also thought to play a role 
in the development of OSSN, perhaps in combination with 
other risk factors such as UV-B exposure. Investigators have 
detected evidence of active HPV infection by polymerase 
chain reaction in CIN lesions (Karcioglu and Issa 1997; Scott 
et al 2002), although it is clear that not all patients infected 
with HPV develop CIN.
Wide surgical excision has been considered the treatment 
of choice for OSSN lesions and specialized techniques for 
decreasing recurrence rates have been described (Shields 
et al 1997). Despite adjunctive cryotherapy, intraoperative 
application of alcohol, and other precautions, recurrence rates Clinical Ophthalmology 2008:2(3) 509
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for OSSN following excision range between 15%–52% (Lee 
and Hirst 1995). Incomplete excision with positive surgi-
cal margins has been identiﬁ  ed as a major risk factor for 
recurrence. Erie and colleagues (1986) showed that excised 
lesions with negative surgical margins had a recurrence rate 
of 5%, whereas the recurrence rate in those lesions that were 
incompletely excised increased to 53%. Similarly, Pizzarello 
and Jakobiec (1978) found that if dysplastic tissues were 
left at the surgical margin, there was a 69% recurrence rate. 
The more severe grades of OSSN also appear to recur at 
higher rates; CIN lesions have a recurrence rate of 17%–24% 
whereas squamous cell carcinoma recurs in 30%–41% of 
cases following surgical excision (Erie et al 1986). When 
adjunctive cryotherapy is used with surgical excision, recur-
rence rates appear to be reduced, ranging between 7%–22% 
(Divine and Anderson 1983; Dutton et al 1984; Peksayar 
et al 1989). Cryotherapy is thought to act through its direct 
destructive effects on cells as well as the obliteration of the 
microcirculation in the areas treated, resulting in ischemic 
infarction of abnormal tissues. Other treatment modali-
ties used for OSSN include beta-radiation therapy (Elkon 
and Constable 1979; Jones et al 1991), gamma radiation 
(Goldberg et al 1963), immunotherapy with dinitrochloro-
benzene (DNCB) (Ferry et al 1976), and the excimer laser 
for corneal disease (Dausch et al 1994). When considering 
aggressive treatment options such as enucleation or even 
exenteration, it should be kept in mind that ocular invasion 
and systemic metastasis are uncommon occurrences with 
OSSN (Lee and Hirst 1995).
Over the past ten years, there has been a paradigm shift 
in the treatment approach of OSSN. Topical agents are now 
commonly employed for a wide spectrum of OSSN lesions, 
being used by clinicians as both adjunctive and primary 
therapy (Frucht-Pery et al 1997; Stone et al 2005). Through 
the work of various investigators, topical MMC has been 
established as an effective primary treatment option for 
OSSN lesions. Rozenman and Frucht-Pery (2000) published 
a case series of 8 patients who had small, superﬁ  cial OSSN 
lesions (8 mm in diameter) treated with topical MMC as 
primary therapy. In all eight patients, the size of the CIN 
started to decrease with one course of therapy with 0.02% 
MMC given for 14 days, although in ﬁ  ve cases, a second 
course of MMC was required to eradicate the lesions. There 
were also two treatment failures; one case required an 
excisional biopsy for persistent disease after two courses of 
MMC, and another patient developed a clinical recurrence 
11 months later that was treated successfully with a third 
course of MMC. This paper was illustrative in that even with 
small, superﬁ  cial OSSN lesions, repeated courses of topical 
MMC were required to achieve tumor regression. Further-
more, the regrowth of CIN occurred within the ﬁ  rst year of 
treatment with MMC, indicating that some neoplastic cells 
survived courses of topical therapy despite the observation 
of “complete” clinical regression. Wilson and colleagues 
(1997) reported a case series of 7 patients with diffuse CIN 
who were considered poor surgical candidates or those who 
had experienced recurrences despite prior surgical treatment. 
Three patients had moderate to severe dysplasia and four 
patients had carcinoma in situ. In this protocol, patients used 
topical MMC 0.04% for 7 day cycles which were repeated 
until tumor control was achieved. With this regimen, six 
of the seven eyes had a complete clinical regression with a 
maximum of 21 days of therapy, with one patient requiring 
surgical excision and adjunctive cryotherapy for a partial 
response. Topical MMC appeared to be effective in this 
group of patients with more resistant CIN lesions, although 
a stronger concentration of 0.04% MMC was employed. 
Prabhasawat and colleagues (2005) used a lower dose of 
MMC (0.02%), similar to the regimen used by Rozenman, to 
treat a group of patients with recurrent or extensive OSSN. 
The patients in this study used 0.02% MMC continuously 4 
times daily until the tumor completely regressed, as observed 
clinically and proven by impression cytology. This regi-
men was successful in six of the seven cases, for a success 
rate of 85.2%. The tumor elimination time ranged between 
2–18 weeks and the mean duration of MMC treatment was 
5.4 weeks (range, 2–14 weeks). The authors noted that the 
lower dosage allowed patients to tolerate the therapy for a 
longer duration than had been reported in the Wilson series, 
although the total time to tumor elimination was similar to 
the higher dose interval treatment (Heigle et al 1997; Wilson 
et al 1997).
Several authors have used topical MMC as a surgical 
adjunct for OSSN lesions, both preoperatively to decrease 
the size of diffuse lesions before surgical excision and 
postoperatively to decrease recurrences (Akpek et al 1999; 
Frucht-Pery et al 2002; Kemp et al 2002; Chen et al 2004; 
Shields et al 2005). Shields and colleagues reported their 
experience using MMC as a neoadjuvant chemotherapy 
agent for tumor reduction (chemoreduction) prior to the 
surgical resection of thick, extensive conjunctival SCC 
(Shields et al 2005). Their protocol involved repeating 7 
day treatment cycles until no further regression was evident 
or the patient became intolerant of the toxic effects of the 
medication. Surgery was performed at least 2 weeks or more 
following discontinuation of MMC to allow for recovery of Clinical Ophthalmology 2008:2(3) 510
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the conjunctiva and adequate wound healing. In this case 
series, follow-up was 14 months in one case, 22 months in 
another case, and not mentioned in the 3rd case. The authors 
reported that chemoreduction was effective in reducing the 
tumor base a mean of 57% using an average of 4 cycles of 
topical MMC. Postoperative MMC has also been used by 
several authors as adjunctive therapy to reduce recurrence 
rates. Chen and colleagues (2004) reported the clinical 
outcomes of topical MMC used as adjunctive treatment 
following primary excision of OSSN (Chen et al 2004). In 
this study, 27 primary OSSN lesions in 26 patients were 
treated with surgical excision, followed by topical MMC. 
All cases were treated with one week courses of MMC 
0.04% four times a day, after complete epithelial healing. 
Nineteen patients received three courses and eight cases 
received two courses due to ocular toxicity. It was not men-
tioned whether the surgical margins were positive in these 
cases. With a mean follow-up of 27 months, there were no 
tumor recurrences reported in this group, and the authors 
concluded that MMC treatment following surgical excision 
was well-tolerated and decreased the recurrence rates of 
OSSN (Chen et al 2004). Other authors have reported similar 
outcomes with postoperative MMC following excision of 
OSSN lesions, albeit with smaller numbers of cases (Akpek 
et al 1999; Frucht-Pery et al 2002).
Table 2 summarizes the clinical reports on the use of 
topical MMC for OSSN. For the purposes of our review, 
treatment failure was deﬁ  ned as persistent disease despite 
repeated courses of topical treatment necessitating surgical 
excision, or clinical evidence of recurrence or regrowth after 
the last course of topical treatment. When used for superﬁ  cial 
disease (ie, dysplasia, carcinoma in situ, recurrent disease), 
the success rate for topical agents compares favorably to 
other modalities; overall recurrence rate among 38 patients 
treated was 24%, with variable lengths of follow-up between 
the 5 studies with CIN patients. Interestingly, both 0.02% 
and 0.04% concentrations have been used successfully for 
CIN, although in general, shorter courses were required with 
the stronger concentration to obtain an adequate clinical 
response. For invasive SCC, the recurrence rate was only 5%, 
although there were only 19 patients identiﬁ  ed in this review 
among 5 authors. The case series reported by Frucht-Pery and 
colleagues (2002) consisted of 5 patients with conjunctival 
SCC that were referred after incomplete surgical excision. 
In this series, all 5 patients were shown to have negative 
conjunctival biopsies after being treated with topical MMC. 
Table 2 Summary of clinical studies of topical agents used as primary therapy for OSSN
Author Agent-DX  No.  cases  Treatment  Surgery  Follow-up  Dose  Regimen
     failure    (months)    (QID/weeks)
Heigle et al 1997  MMC/SCC  2  0  0  7–9  0.04%  3
 MMC/CIN  1  0  0  6  0.04%  3
Wilson et al 1997  MMC/CIN  7  1  1  2–16  0.04%  1–3
Frucht-Pery et al 1997  MMC/CIN  16  5  0  3–23  0.02%–4%  1–4
 MMC/SCC  1  1  1  6  0.02%  4
Rozenman et al 2000  MMC/CIN  8  2  1  24–44  0.02%  2–4
Shields et al 2002  MMC/SCC  10  0  0  6–50  0.04%  1–4
Frucht-Pery et al 2002  MMC/SCC  5  0  0  18–37  0.02%–0.04%  4–6
Prabhasawat et al 2005  MMC/CIN  6  1  0  2–52  0.02%  2–14
 SCC  1  0  0  33  0.02%  5
Totals    57 10  3    
de Keizer et al 1986  5-FU/CIN  2  0  0    1% 
Yeatts et al 1995  5-FU/CIN  3  0  0  10–18  1%  5–6
 5-FU/SCC  2  2  2  15–36  1%  6–7
Yeatts et al 2000  5-FU/CIN  7  3  0  7–36  1%  QID/4–24 d
Midena et al 2000  5-FU/SCC  8  1  0  13–53  1%  4
Totals    22 6  2    
Maskin 1994  IF/CIN  1  0  0  9  1 m/ml  8
Vann and Karp 1999  IF/CIN  6  0  0  7.2  1 m/ml  8–20
Karp et al 2001  IF/CIN  5  1  0  7–28  1 m/ml  16
Schechter et al 2002  IF/CIN  1  0  0  19  1 m/ml  20
Boehm and Huang 2004  IF/CIN  7  2  0  8–17  1 m/ml  12
Totals    20 3  0    
Abbreviations: DX, clinical diagnosis; CIN, conjunctival intraepithelial neoplasia; SCC, squamous cell carcinoma; MMC, mitomycin-C; OSSN, ocular surface squamous neoplasia; 
5-FU, 5-ﬂ  uorouracil; IF, interferon; d, days; m/ml, million units per ml; QID, 4x per day.Clinical Ophthalmology 2008:2(3) 511
Topical treatment options for conjunctival neoplasms
Shields and colleagues (2002) also reported excellent clinical 
results in ten patients with conjunctival and corneal SCC 
treated with topical MMC as primary therapy. All of these 
patients had clinically evident tumors and complete tumor 
regression was documented in all ten cases; no recurrences 
have been observed with a mean follow-up of 22 months. In 
general, the stronger concentration of 0.04% MMC was used 
by the majority of authors for invasive SCC, with a treatment 
duration ranging between 3–6 weeks.
OSSN and 5-FU
There are a limited number of studies describing the use 
of 5-FU for OSSN (de Keizer et al 1986; Yeatts et al 1995; 
Midena et al 2000). de Keizer and collagues (1986) reported 
the successful treatment of two patients affected by carcinoma 
in situ of the conjunctiva and cornea with 1% topical 5-FU 
(de Keizer et al 1986). Then Yeatts and colleagues (1995) 
reported using 5-FU drops to treat six patients with a variety 
of OSSN lesion: three cases of carcinoma in situ, one case of 
invasive carcinoma, and two cases of intraepithelial dyspla-
sia. These authors used 5-FU four times daily for 14–21 day 
cycles with no long-term side effects, although two of the six 
patients developed tumor recurrences that required surgical 
excision. Yeatts and colleagues (2000) later published a 
series of 7 patients with CIN lesions with a minimum of 7 
months follow-up. In this study, pulsed dosing of 1% 5-FU 
was used, with durations of 2–4 days for each cycle. The 
number of initial treatment cycles was two to six, with the 
time between cycles being 30–45 days. Three patients in 
this series experienced tumor recurrence; two patients were 
successfully treated with additional cycles of topical 5-FU 
and one patient required treatment with topical MMC for 
persistent disease. Finally, Midena and colleagues (2000) 
reported the results of a prospective, nonrandomized study 
to evaluate the efﬁ  cacy of topical 5-ﬂ  uorouracil (5-FU) in 
the treatment of recurrent, partially excised, and selected 
untreated conjunctival SCC. This study had a standardized 
protocol for following patients and the clinical results were 
not inﬂ  uenced by concomitant surgery or other treatments. 
All of the patients in this study had invasive SCC, and they 
were treated daily for a course of 4 weeks with topical 1% 
5-FU. Cytologic smears were performed at 1, 3, and 6 months. 
At the last follow-up examination, a conjunctival biopsy was 
performed at the site of the original lesion, except for two 
patients who refused any surgery. Patients in the study had 
a minimum follow up of 13 months, with a range of 13–53 
months and a mean of 27 months. Seven patients had com-
plete and stable regression of their conjunctival lesions. One 
patient had a clinical local recurrence, six months after topical 
chemotherapy. He was successfully retreated with a second 
4 week course of topical 5-FU. Overall, no malignant cells 
were found after the 4 week course of treatment, except for 
the recurrent case, on examination of conjunctival cytological 
smears. In all cases, post-treatment biopsies conﬁ  rmed the 
accuracy of these cytological results. In summary, all eight 
cases with SCC were treated with topical 5-FU alone with 
remission of the disease after one or more courses of local 
chemotherapy.
Despite the signiﬁ  cant recurrence rate observed in the 
earlier studies with 5-FU, the Midena paper demonstrated 
that topical chemotherapy with 5-FU alone was effective in 
eradicating SCC in these patients without major and/or long 
term side effects. Although it is difﬁ  cult to make conclusions 
based on one report, this pilot study was well-designed and 
clinicians should be encouraged about the prospect of curing 
invasive SCC lesions with a 4 week course of topical 5-FU. 
In addition, 5-FU may have a more favorable side effect 
proﬁ  le than topical MMC, although more studies are needed 
to validate this potential advantage.
OSSN and alpha-interferon
Between 1993 and 1999, there were encouraging case reports 
of patients with conjunctival and corneal CIN being treated 
successfully with interferon (Maskin 1994; Vann and Karp 
1999; Schechter et al 2002). Topical interferons for OSSN 
were ﬁ  rst reported to be efﬁ  cacious in a case reported by 
Maskin (1994). A subsequent paper by Vann and Karp (1999) 
described the successful use of a combination of intralesional 
and topical interferon in six patients with biopsy-proven 
primary or recurrent CIN. Although the follow-up in these 
early case reports was only 9–19 months, complete resolu-
tion of these lesions was noted, and patients were able to 
tolerate topical interferon therapy for 2–5 months. Karp 
and colleagues (2001) have also published a case series of 5 
patients treated with topical interferon for corneal and con-
junctival intraepithelial neoplasia, 2 of whom were treated 
for recurrent disease. One patient received almost 4 months 
of continuous therapy (17 weeks), with clinical resolution 
noted at 13 weeks. The only patient who experienced a recur-
rence in this series was treated successfully with a second 
course of topical interferon which lasted 2 months, and this 
was followed by another 8 months of maintenance therapy. 
Boehm and Huang (2004) reported using topical interferon 
as a single therapeutic agent in the treatment of recurrent 
corneal and conjunctival intraepithelial neoplasia. All seven 
patients in this series had suffered recurrences after surgical Clinical Ophthalmology 2008:2(3) 512
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excision, and with topical interferon alone, 5 of 7 patients 
were successfully treated. Two patients experienced clinical 
recurrences, noted at 2 months and 1 year of follow-up, and 
in both cases, topical therapy was re-instituted. The average 
duration of treatment in this series was 14.1 weeks, and 
the average period to resolution of disease was 14.5 weeks 
(range, 5–24 weeks). Ocular side effects were not observed 
in any of these patients.
Summary of OSSN and topical agents
For the treatment of both preinvasive and invasive OSSN 
lesions, topical MMC and 5-FU have been shown to be 
effective when used as primary therapy. A comparative trial 
has not been performed between these two agents, and it is 
therefore difﬁ  cult to compare clinical results between various 
series. Topical MMC has a longer track record, and it may 
prove be more versatile, since it has been used as primary 
therapy, as a preoperative neoadjuvant agent, and a postop-
erative therapy to decrease recurrence rates. 5-FU appeared to 
have slightly higher recurrence rates in earlier studies, but the 
paper by Midena and colleagues (2000) clearly showed that 
topical 5-FU was very effective in the primary treatment 
of invasive SCC. When considering both MMC and 5-FU, 
recurrences respond quite well to second and third courses 
of topical treatment, and few patients require surgical inter-
vention. Overall, patients treated with 5-FU may experience 
fewer side effects than MMC during the treatment course, 
although permanent ocular toxicity with MMC has not been 
reported when treating OSSN lesions. Topical interferon 
may play a role in patients who are intolerant of topical che-
motherapeutic agents, although the number of cases treated 
successfully with this therapy is small and prolonged courses 
of treatment are required (minimum of 3–4 months).
Pagetoid spread of sebaceous 
cell carcinoma
Sebaceous gland carcinoma of the periocular region may 
present with pagetoid extension of the conjunctiva in 
41%–80% of cases (Kass and Hornblass 1989). Despite the 
common practice of using map biopsies to deﬁ  ne the extent 
of pagetoid extension, surgical eradication of the tumor is 
complicated by the ill-deﬁ  ned and multifocal nature of the 
intraepithelial involvement in many patients with sebaceous 
cell carcinoma (Putterman 1986). Kemp and colleagues 
(2002) reported treating two patients with pagetoid exten-
sion from sebaceous cell carcinoma with topical MMC; in 
one case MMC 0.04% was used as a preoperative adjunct 
before surgical excision, and in the second case, topical 
MMC was used both intraoperatively and postoperatively. 
The second patient developed a clinical recurrence which 
was treated with another course of topical MMC 0.04% and 
a subsequent biopsy 22 months later showed no evidence of 
disease. Shields and colleagues (2002) presented a series of 
3 patients with pagetoid invasion of the conjunctiva treated 
successfully with topical MMC. After conﬁ  rmation of dis-
ease by map biopsies, patients were started on topical MMC 
0.04% with 7 day cycles; the exact duration of treatment was 
not reported although the authors commented that treatment 
courses were repeated until all epithelial disease was judged 
to be clinically regressed. None of the three patients appeared 
to suffer from a recurrence, and two of the cases had negative 
post-treatment biopsies, although the longest follow-up was 
only 17 months. It should be emphasized that topical MMC 
should only be used in selected cases of biopsy conﬁ  rmed 
sebaceous cell carcinoma as a surgical adjunct for pagetoid 
extension. In such cases, patients can be treated with topi-
cal MMC for residual intraepithelial disease following wide 
surgical excision of the tumor mass. Caution is also warranted 
when considering MMC in any patient who has undergone 
extensive eyelid reconstruction, given that compromised 
eyelid function is likely to be accompanied by ocular surface 
abnormalities. It is also important to delay topical treatment 
until all surgical wounds are healed, to avoid more serious 
ocular side effects related to wound healing or intraocular 
penetration of the drug. Tumuluri and colleagues (2007) 
reported signiﬁ  cant corneal complications in a 78 year old 
man with pagetoid invasion of the conjunctiva treated with 
topical MMC (Tumuluri et al 2004). Following wide tumor 
excision and complete upper lid reconstruction, the patient 
was treated with a total of six weeks of topical MMC 0.02% 
four times a day for epithelial disease. Although the patient 
was recurrence-free at two years of follow-up, his course 
was complicated by corneal epithelial toxicity and ulceration 
requiring lateral tarsorrhaphy.
Complications of ocular topical 
therapy
Ocular toxicity of MMC
Almost all patients treated with topical MMC experience 
transient side effects, manifesting as conjunctival injection, 
chemosis, and/or keratitis (Demirci et al 2000; Frucht-Pery 
et al 2002; Kurli and Finger 2005; Khong and Muecke 2006). 
In Kurli’s series, all patients who were treated for 28 days 
developed keratoconjunctivitis, which took 4–6 weeks to 
resolve (Kurli and Finger 2005). It is not uncommon for Clinical Ophthalmology 2008:2(3) 513
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patients to discontinue treatment prematurely due to severe 
keratoconjunctivitis (Demirci et al 2000). Not surprisingly, 
patients receiving shorter courses of MMC appear to expe-
rience less severe keratoconjunctivitis than those receiving 
longer courses. Lower concentrations of MMC (0.02%) also 
appear to cause fewer side effects (Prabhasawat et al 2005). 
Therefore, it appears that ocular surface toxicity occurs in 
a predictable, dosage-dependent pattern. When used as an 
adjunct to surgical excision, several authors have noted that 
postoperative MMC does not prevent wound closure or cause 
wound dehiscence, if instituted after epithelial healing has 
occurred (Shields et al 2001). Despite the ocular surface 
disease, almost all of the patients treated with topical MMC 
maintain their pretreatment visual acuity (Demirci et al 2000; 
Pe’er and Frucht-Pery 2005). Permanent ocular side effects 
with topical MMC therapy are unusual. One of the patients in 
Kurli’s series developed corneal pannus and lost seven lines 
of vision (Kurli and Finger 2005). Recurrent epithelial defects 
and/or pannus formation may occur secondary to limbal stem 
cell deﬁ  ciency, and caution is warranted in treating patients 
who have had surgical alteration of this area (Dudney and 
Malecha 2004). Two patients in Kurli’s series also gradually 
developed cataracts 2–3 years after topical MMC therapy, 
although direct causation was not proven. Intumescent cata-
ract after topical mitomycin for conjunctival melanomas has 
been reported, possibly due to intraocular penetration of the 
drug (Sacu et al 2003). No cases of scleral or corneal melting 
have been reported, as has occurred following intraoperative 
application of MMC in glaucoma and pterygium surgery. An 
intact epithelium probably prevents absorption of these drugs 
into deeper tissue layers, and therefore topical MMC should 
not be given to any patient with a corneal or conjunctival 
epithelial defect. Epiphora secondary to punctal stenosis has 
been reported (Khong and Muecke 2006), emphasizing the 
need to place temporary punctal plugs or to have patients 
to occlude the lower punctum for at least ﬁ  ve minutes after 
instilling the topical mitomycin. Occluding the punctum also 
minimizes the potential for inducing adverse changes in the 
nasopharyngeal epithelium with topical MMC therapy.
Ocular toxicity of 5-Fluorouracil
Although the side effect proﬁ  le of topical 5-FU has not been 
extensively studied, clinical studies performed to date have 
reported no long-term side effects with the ocular admin-
istration of this drug. When used continuously for 28 days 
in the study by Midena and colleagues (2000), transient 
conjunctivitis and superﬁ  cial keratitis were observed in all 
patients during the third or fourth week of treatment. This side 
effect was easily controlled with topical steroid drops given 
for 5–6 days. When Yeatts modiﬁ  ed the 5-FU protocol into 
a pulsed dosing regimen, he obtained similar clinical results 
to the Midena protocol, but no adverse ocular reactions were 
noted. Scarring of the lacrimal drainage apparatus reported 
with systemic 5-FU (Shapiro et al 1985), has not been found 
with topical administration. The cytologic changes in the 
epithelium associated with MMC have not been observed 
with topical 5-FU.
Ocular toxicity of interferon
In general, topical interferon is thought to have fewer side 
effects compared with other agents. No patient in the study 
published by Boehm experienced any side effects, despite 
prolonged use of topical interferon (Boehm and Huang 2004). 
Schecter and colleagues (2002) reported localized conjunc-
tival injection and folliculosis in 4 of 7 patients treated with 
topical interferon, which they attributed to the vehicle used 
in their topical preparation. Kobayashi and colleagues (2002) 
also reported superﬁ  cial punctuate keratopathy in one case 
treated with interferon. Transient fever and muscle pain have 
been reported as side effects of subconjunctival interferon 
(Vann and Karp 1999; Kobayashi et al 2002).
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